Medroxalol RMI81968|cas:56290-94-9|西域试剂

Medroxalol RMI81968,99.66%

产品编号：Bellancom-101656| CAS NO：56290-94-9| 分子式：C₂₀H₂₄N₂O₅| 分子量：372.41

美洛沙罗（RMI81968）是一种口服活性肾上腺素能受体拮抗剂，阻断α-和β-肾上腺素能受体。美洛沙罗具有抗高血压和血管扩张作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-101656		￥7500.00	杭州北京（现货）
Bellancom-101656		￥11800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Medroxalol RMI81968

产品介绍

Medroxalol (RMI81968) 是一种具有口服活性的肾上腺素受体拮抗剂，可阻断 α- 和 β- 肾上腺素受体。Medroxalol 具有抗高血压和血管扩张的活性。

生物活性

Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects.

体外研究

Medroxalol (0.1-10 μM; 20 min) shows α- and β-adrenergic receptor antagonism in isolated rabbit aortic strip.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Isolated rabbit aortic strip
Concentration:	0.1-10 μM
Incubation Time:	20 min
Result:	Showed pA₂ values of 6.09 and 7.73 for α-adrenergic receptors and β-adrenergic receptors, respevtively.

体内研究
(In Vivo)

Medroxalol (oral gavage; 12.5-50 mg/kg; once daily; 12 d) treatment shows antihypertensive activity in spontaneously hypertensive rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male spontaneously hypertensive rats (SHR)
Dosage:	12.5, 25, or 50 mg/kg
Administration:	Oral gavage; 12.5, 25, or 50 mg/kg; once daily; 12 days
Result:	Produced a dose-related fall in blood pressure.

体内研究

Medroxalol (oral gavage; 12.5-50 mg/kg; once daily; 12 d) treatment shows antihypertensive activity in spontaneously hypertensive rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male spontaneously hypertensive rats (SHR)
Dosage:	12.5, 25, or 50 mg/kg
Administration:	Oral gavage; 12.5, 25, or 50 mg/kg; once daily; 12 days
Result:	Produced a dose-related fall in blood pressure.

体内研究

Medroxalol (oral gavage; 12.5-50 mg/kg; once daily; 12 d) treatment shows antihypertensive activity in spontaneously hypertensive rats.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male spontaneously hypertensive rats (SHR)
Dosage:	12.5, 25, or 50 mg/kg
Administration:	Oral gavage; 12.5, 25, or 50 mg/kg; once daily; 12 days
Result:	Produced a dose-related fall in blood pressure.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (134.26 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6852 mL	13.4261 mL	26.8521 mL
5 mM	0.5370 mL	2.6852 mL	5.3704 mL
10 mM	0.2685 mL	1.3426 mL	2.6852 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Dage RC, et al. Cardiovascular properties of medroxalol, a new antihypertensive drug. J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):299-315. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

上游产品 1
56290-93-8
下游产品 0

Medroxalol RMI81968,99.66%

Medroxalol RMI81968

化学品安全说明书(MSDS)

质检证书(COA)

在线咨询